PDUFA Date
RVMD: PDUFA: rasonque
August 26, 2026 · rasonque · approval. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- August 26, 2026
- Company
- REVOLUTION MEDICINES, INC. (RVMD)
- Drug
- rasonque
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
PDUFA Dateapproval
PDUFA: rasonque
- Drug
- rasonque
- Indication
- 1 INDICATIONS AND USAGE RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. RASONQUE is an inhibitor of the RAS GTPase family, indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. ( 1 )